• Something wrong with this record ?

A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor

L. Mumford, SV. Fuggle, J. Martorell, A. Slavcev, A. Iniotaki, GW. Haasnoot, S. Heidt, FHJ. Claas

. 2021 ; 64 (-) : 101354. [pub] 20201201

Language English Country Netherlands

Document type Editorial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019389

Immunisation against Human Leucocyte Antigens (HLA) can be caused by pregnancy, blood transfusion, or organ transplants. The HLA antibody status of a given patient significantly influences their access and waiting time to transplant. For some highly sensitised patients (HSP) there is hardly any suitable donor available in the deceased donor pool of their allocation organisation and therefore they wait a very long time before being offered a kidney for transplant. Especially patients with rare HLA phenotypes in relation to the actual donor pool are waiting extremely long. As HLA phenotypes are different in the various European populations, we hypothesized that extension of the donor pool outside the respective allocation system will increase the chance of receiving a compatible transplant for this subgroup of highly sensitised patients. One of the objectives of the EUROSTAM project, (a Europe-wide Strategy to enhance Transplantation of highly sensitised patients on the basis of Acceptable HLA Mismatches) was to develop a tool to compare the chance of transplanting HSP in different European populations with donor organs from within and outside their own donor pool. Information on the HLA type and ABO blood group of the actual donor population, as well as the acceptable mismatches of long waiting HSP were obtained from the EUROSTAM partner organizations i.e. Eurotransplant (ET), UK National Health Service Blood and Transplant (NHSBT), Barcelona, Prague and Athens. Results from simulations using the newly developed tool shows that 195 (27%) of the 724 long waiting highly sensitised patients registered at each partner organisation have increased chances of transplant in a different European donor pool. This makes a strong case for sharing kidneys between European countries for selected difficult to transplant patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019389
003      
CZ-PrNML
005      
20210830100941.0
007      
ta
008      
210728s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.trim.2020.101354 $2 doi
035    __
$a (PubMed)33276060
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Mumford, Lisa $u Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, UK
245    12
$a A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor / $c L. Mumford, SV. Fuggle, J. Martorell, A. Slavcev, A. Iniotaki, GW. Haasnoot, S. Heidt, FHJ. Claas
520    9_
$a Immunisation against Human Leucocyte Antigens (HLA) can be caused by pregnancy, blood transfusion, or organ transplants. The HLA antibody status of a given patient significantly influences their access and waiting time to transplant. For some highly sensitised patients (HSP) there is hardly any suitable donor available in the deceased donor pool of their allocation organisation and therefore they wait a very long time before being offered a kidney for transplant. Especially patients with rare HLA phenotypes in relation to the actual donor pool are waiting extremely long. As HLA phenotypes are different in the various European populations, we hypothesized that extension of the donor pool outside the respective allocation system will increase the chance of receiving a compatible transplant for this subgroup of highly sensitised patients. One of the objectives of the EUROSTAM project, (a Europe-wide Strategy to enhance Transplantation of highly sensitised patients on the basis of Acceptable HLA Mismatches) was to develop a tool to compare the chance of transplanting HSP in different European populations with donor organs from within and outside their own donor pool. Information on the HLA type and ABO blood group of the actual donor population, as well as the acceptable mismatches of long waiting HSP were obtained from the EUROSTAM partner organizations i.e. Eurotransplant (ET), UK National Health Service Blood and Transplant (NHSBT), Barcelona, Prague and Athens. Results from simulations using the newly developed tool shows that 195 (27%) of the 724 long waiting highly sensitised patients registered at each partner organisation have increased chances of transplant in a different European donor pool. This makes a strong case for sharing kidneys between European countries for selected difficult to transplant patients.
650    _2
$a HLA antigeny $x genetika $x imunologie $7 D006680
650    _2
$a histokompatibilita $7 D006648
650    _2
$a testování histokompatibility $x metody $7 D006650
650    _2
$a lidé $7 D006801
650    _2
$a imunizace $7 D007114
650    12
$a transplantace ledvin $7 D016030
650    _2
$a dárci tkání $7 D014019
650    _2
$a příjemce transplantátu $7 D066027
650    _2
$a seznamy čekatelů $7 D014850
651    _2
$a Evropa $7 D005060
655    _2
$a úvodníky $7 D016421
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fuggle, Susan V $u Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, UK; Oxford Transplant Centre, Nuffield Department of Surgical Sciences, University of Oxford, UK
700    1_
$a Martorell, Jaume $u Hospital Clinic, Barcelona, Spain
700    1_
$a Slavcev, Antonij $u Dept. Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Iniotaki, Aliki $u National Tissue Typing Center, General Hospital of Athens "G. Gennimatas", Athens, Greece
700    1_
$a Haasnoot, Geert W $u Eurotransplant Reference Laboratory, Leiden University Medical Centre, Leiden, the Netherlands
700    1_
$a Heidt, Sebastiaan $u Eurotransplant Reference Laboratory, Leiden University Medical Centre, Leiden, the Netherlands
700    1_
$a Claas, Frans H J $u Eurotransplant Reference Laboratory, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: fhjclaas@lumc.nl
773    0_
$w MED00006022 $t Transplant immunology $x 1878-5492 $g Roč. 64, č. - (2021), s. 101354
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33276060 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100941 $b ABA008
999    __
$a ok $b bmc $g 1690253 $s 1139835
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c - $d 101354 $e 20201201 $i 1878-5492 $m Transplant immunology $n Transpl Immunol $x MED00006022
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options